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Abstract
Background: Whilst there is broad agreement on what constitutes high quality health care for
people with diabetes, there is little consensus on the most efficient way of delivering it. Structured
recall systems can improve the quality of care but the systems evaluated to date have been of
limited sophistication and the evaluations have been carried out in small numbers of relatively
unrepresentative settings. Hartlepool, Easington and Stockton currently operate a computerised
diabetes register which has to date produced improvements in the quality of care but performance
has now plateaued leaving substantial scope for further improvement. This study will evaluate the
effectiveness and efficiency of an area wide 'extended' system incorporating a full structured recall
and management system, actively involving patients and including clinical management prompts to
primary care clinicians based on locally-adapted evidence based guidelines.
Methods: The study design is a two-armed cluster randomised controlled trial of 61 practices
incorporating evaluations of the effectiveness of the system, its economic impact and its impact on
patient wellbeing and functioning.
Background
Delivering care to people with diabetes
There is broad, international agreement over what consti-
tutes high quality health care for people with diabetes
[1,2]. This will be enshrined in a National Service Frame-
work for people with diabetes, due in summer 2002.
However, in the face of poor current performance [3,4]
the most efficient method of delivering care remains un-
clear [4]. Following a 1994 systematic literature review [5]
suggesting structured care improved patient care, an edito-
rial in the British Medical Journal concluded that more
evaluative research was needed before widespread adop-
tion of any of the models could be recommended [6]. A
subsequent systematic review of routine surveillance of
patients with diabetes by Griffin and Kinmonth [7] con-
cluded "Computerised central recall, with prompting for pa-
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tients and their family doctors, can achieve standards of care as
good or better than hospital outpatient care, at least in the short
term. The evidence supports provision of regular prompted re-
call and review of people with diabetes by willing general prac-
titioners and demonstrates that this can be achieved, if suitable
organisation is in place'. However, the evidence base on
which these conclusions are based is limited in several
ways. Firstly there are only five randomised controlled tri-
als (RCTs) involving 1058 patients. All of these studies are
'patient randomised" trials, thus potentially under-esti-
mating the effectiveness of the intervention (see Study De-
sign). They were all evaluating more or less selected
patients and general practices and none of them were ex-
plicitly evaluating a UK National Health Service (NHS)
service area wide intervention. Only one of the four UK
based studies evaluated patient based outcomes and in-
cluded an economic assessment and this study only in-
volved patients from three general practices [8]. Thus, the
effectiveness of an area wide, patient focussed, structured
recall and management system (in terms of process of
care, patient outcome and economic impact) remains un-
known.
The current system
The current computerised diabetes management system
runs in Hartlepool, Easington and Stockton, three Primary
Care Group (PCG) areas, in the Northern and Yorkshire
Region. It was introduced to all 36 general practices in
Hartlepool and Easington Districts in mid-1995. Stockton
(25 practices) agreed to join the system in 1999 and it was
operational there by October 2000. There are three key
components to the current system:
1. A central register of patients with diabetes.
2. A structured minimum dataset to be completed and re-
turned to the central register.
3. The provision of both patient specific and aggregated
data to both patients and clinicians.
The system (developed by Westman Medical Software) al-
lows three methods of collection of data at each contact
with a patient with diabetes who is registered on the data-
base. Two methods use a standard form completed by cli-
nicians to collect data concordant with the UK minimum
data set [9]. Within secondary care, forms are completed
at every new patient or annual review. In primary care,
forms are completed by the practice nurse (usually) or
general practitioner, either opportunistically or at practice
diabetic clinics. In both cases, the completed data forms
are sent to the Diabetes Register Facilitator for data entry.
Thirdly, the hospital laboratory provides a monthly
download of laboratory test details (e.g. HbA1c). A pa-
tient can be identified as having diabetes and added to the
register by any permutation of one or more of these three
routes. Feedback of individual patients' data, including re-
view status, is provided to general practices quarterly. This
feedback is 'passive' in that it does not explicitly prompt
either patients or doctors as to required actions. Audit
packages within the software can audit on every variable
collected. District wide audit is provided on anonymised
aggregated data; individual practice audits (with compar-
isons to other practices) are provided to participating
practices at least annually. Feedback of the data to the pa-
tient (for hospital patients only) is by a patient informa-
tion sheet and to the GP as a standardised letter. A
Diabetes Register Facilitator co-ordinates and updates the
register. A steering group composed of GH, the Diabetes
Register Facilitator and representatives of the PCGs and
patients, oversees the register and deals with issues such as
confidentiality.
Impact of the system to date
Measures of the impact of the system to date relate only to
Hartlepool, Easington and Stockton. The main impact on
patient registration was in its first 12 to 18 months of op-
eration: during 1995, 747 patients were registered on the
system (0.4% prevalence) which had increased to 3867
(1.8% prevalence) by the end of 1996. The increase in reg-
istration has stabilised since then, reaching 4324 (2%
prevalence) by 1999. During 1999, 70% of registered pa-
tients attended a clinic; 52% had their feet examined and
51% had their eyes examined. Seventy three per cent had
an HbA1c result recorded and 69% a blood pressure
measurement. These figures are similar to those reported
by other centres using the same system [10].
The need for an extended system
Recording of clinical measures increased during the first
few years of operation of the system but began to plateau
more recently (for example, 50% of patients had an
HbA1c recorded during 1996, compared to 60% in 1997
and 63% in 1998). This plateauing of performance has
been reported by others [10]. We believe that this is due
to a lack of coordination (patients being lost to follow up)
and lack of prompting of clinicians to deliver appropriate
clinical interventions. Furthermore, given that most pa-
tients with diabetes are primarily seen in primary care the
greatest potential impact is from optimising and extend-
ing the system in primary care. In order to address these
shortcomings the additional key components, over and
above those already in the system, will be:
1. Locally adapted evidence based guidelines for the man-
agement and follow up of patients with diabetes.
2. Automated prompts to patients and primary care clini-
cians that a review consultation is necessary.BMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/5
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3. A structured management sheet (including patient spe-
cific management suggestions based on (1)).
4. An enhanced monitoring system to follow up reasons
for non-attendance from both patients and clinicians and
to re-schedule appointments, based on nonreturn of a
completed management sheet.
5. Patient feedback for patients in primary care.
There is some limited supportive trial evidence for these
developments, although the existing studies involved
small sample sizes and may not be generalisable to the
NHS [11–13]. In evaluating the system with these extend-
ed features this study will also address the design short-
comings of previous studies of shared care in diabetes [6].
It will be tailored to each practice, PCG defined areas will
be studied, rather than an unrepresentative sample of gen-
eral practices; and the system will be transparent and rep-
licable in other areas.
Methods
Design of the study
The study design is a pragmatic two-arm cluster ran-
domised controlled trial. The unit of randomisation will
be the general practice. Simple patient randomised trials
are rightly considered the most robust method of assess-
ing most health care innovations [14]. This design, how-
ever, cannot be regarded as the gold standard for
evaluating systematic approaches to chronic disease man-
agement, an essentially behavioural field of research
[15,16]. If both intervention and control patients were to
be cared for within the same practice there is the risk that
the management of control patients would be influenced
by the practitioners knowledge of the care of intervention
patients. This would result in an underestimation of the
effect of the intervention [17]. Therefore, practices rather
than patients are the appropriate unit of randomisation
and analysis.
As the current system has been in place for different
lengths of time within the three participating PCGs, we
will stratify the randomisation by PCG. Randomisation
will be performed by a statistician independent of the re-
search team using computer generated numbers to avoid
allocation bias [18].
Study setting and recruitment of practices
The study will be based in the general practices of the
three PCGs of Easington, Hartlepool and Stockton. Since
the recent merger of Hartlepool and North Tees Acute
Trusts all three PCGs are now exclusively served by one
secondary care diabetes service (and thus the one diabetes
register). GH is the lead clinician for diabetes services in
the new Trust.
The 61 general practices in the three PCGs constitute the
target practices for the study and we will attempt to recruit
all practices. The PCG diabetes leads or the PCG clinical
governance leads in all three PCGs have provided letters
confirming their support for the project. We do not envis-
age major difficulties with recruitment, given the need to
agree local guidelines as part of the process involved in the
Trust merger, the likely requirements in the forthcoming
National Service Framework for diabetes, and the 100%
practice coverage with the current diabetes system. We
will (through the PCGs) write to all practices, giving infor-
mation about the project to the senior partner or diabetes
lead and practice manager of practices. Practices will be in-
vited to opt out if they do not wish to be included in the
study – this is an approach we have used successfully be-
fore. The PCG diabetes lead, clinical governance lead and
GH will be co-signatories of this letter. If practices do de-
cline we will collect data on characteristics of non-partici-
pating practices to assess the impact on the
generalisability of the trial's findings. Finally, if there are
significant problems with recruitment, there are other
practices which could be approached in a nearby PCG
(South Tyneside) which uses the same software for its di-
abetes register.
Details of the intervention
Local guidelines and management prompts
A guideline development group will be established to de-
velop local guidelines for the management of diabetes,
based upon available evidence based guidelines (Scottish
Intercollegiate Guidelines Network [19–22](SIGN, 1996,
1997a, 1997b, 1997c), and Effective Care Bulletins
[23,24]. They will also use the forthcoming national dia-
betes guidelines as these become available. The group will
be multidisciplinary and contain primary and secondary
care doctors and nurses, patients and the Diabetes Register
Facilitator [25]. The group will define review periods for
specified patient groups (e.g. patients with diabetes satis-
factorily controlled on diet alone should be reviewed eve-
ry 12 months), referral criteria for patients moving from
primary to secondary care and back and simple decision
rules for the management prompts. These would be of
two types. The first would prompt for actions to be per-
formed and only require their performance to be docu-
mented (e.g. asking for a foot examination to be
performed in a patient who does not have a recorded foot
examination). The second would be more complex and
suggest alterations to clinical management on the basis of
data in the database (e.g. patients with persistently raised
blood pressure should have their anti-hypertensive medi-
cation increased). These decision rules will be integrated
into the recall and management system.BMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/5
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Running the system
The proposed enhancements to the system are designed to
require the primary care team to perform no additional
work over and above the current configuration. The cur-
rent database has a patient identifier, a minimum dataset
and retrieval systems to support the structured recall of pa-
tients. Westman Medical Software has agreed to amend
the system as required. A 'circle of information exchange'
will be established between the participating general prac-
tices and the database. The local guidelines will be used to
adapt the current centralised database, along with the
practices' preferred method of following up patients (for
example, within consultations in routine surgeries or
within special clinics). The central database system will
identify when patients are due for review (based upon the
local guidelines) and will generate a letter to the patient
asking them to make an appointment for a review consul-
tation. Patient information or educational materials could
be included with the letter. At the same time, the central
database will generate a letter to the practice stating that
the patient should be making a review appointment in the
near future. The letter to the practice will include a man-
agement sheet (to be held in the patient's record) to cap-
ture an agreed minimum data set to be collected during
the consultation. This management sheet will also contain
the relevant prompts (as described above).
When the patient is seen in the practice, the primary care
professional (currently this is usually done by the practice
nurse) will complete the management sheet and return a
copy for entry onto the central register within a designated
period of time. This circle of information is broken if the
patient does not visit the general practice as planned or
the general practice does not return the management
sheet to the central register. If this happens, the central
register would alert the Diabetes Register Facilitator who
will ascertain the reason for failure and take appropriate
action, (e.g. send a reminder to the patient, prompt the
practice to return the management sheet).
A range of educational activities will be provided for inter-
vention practices, as part of the usual local structures for
contact with practices, with some additions, These will in-
clude: distribution of information about the trial in local
newsletters; meetings with practice clinical governance
leads; evening meetings for practice nurses (with small
group discussion of the practical implications for inter-
vention practices); and a telephone meeting with the prac-
tice diabetes lead (usually the practice nurse) in each
intervention practice.
Practices in the control arm will continue to receive the re-
call system as currently configured.
Logistical considerations
From the prevalence of patients with diabetes on the cur-
rent register, there will be about 7500 patients on the sys-
tem if 61 practices are recruited. Half of these will be in
intervention practices. On current patterns of usage, we
anticipate there being the need for 1.5 recalls per annum
per patient on the register, resulting in about 6000 recalls
per year for the intervention group. Assuming a 40 week
working year, the system will need to dispatch, receive and
process about 150 forms per group per week.
Identification of patients
Patients for the structured recall and management system
are already identified on the Hartlepool and North Tees
database. As some practices have children registered on
the system, who are under the care of an exclusively sec-
ondary care adolescent service, an age limit of 18 years or
over will be set for inclusion. Practices will be asked to
check lists of their patients on the database regularly
throughout the study. The central database will remove
patients from the recall system who are known to have
died or moved away.
Patient consent
Patients have already consented, or are being consented,
to their data being held within the current diabetes regis-
ter. The study will involve no extra 'routine' data being
collected, and this data will be anonymised before being
sent for analysis; all data held for analysis will be held in
accordance with the Data Protection Act. For the patient-
based questionnaire study, we will seek additional patient
consent to complete one survey. The three relevant Local
Research Ethics Committees have approved the trial.
Data collection
The main study outcome measures will be rates of per-
formance of process of care and the patient based meas-
ures of functional and psychosocial wellbeing. Data will
be collected for 15 months after the start of the interven-
tion. Fifteen months was chosen to allow for patients who
are reviewed every 12 months but fail to attend on initial
invitation.
Process of care variables
Process of care variables will be collected via the compu-
terised database. The exact data to be collected will be de-
termined by both the current content of the database and
the guidelines but will include such data items as rates of
attendance at clinics and annual reviews, conduct of eye
and feet examinations, performance of investigations and
prescribing. We will also collect data on clinical measures
(e.g. HbA1c, and blood pressure levels).BMC Health Services Research 2002, 2 http://www.biomedcentral.com/1472-6963/2/5
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Outcome of care measures
Outcome of care data will be collected, by postal ques-
tionnaire, 15 months after commencement of the study. A
portfolio of validated [26–30] and responsive [30,31] ge-
neric and disease specific instruments will be used to
measure functional and psychosocial variables that will
be potentially influenced by the intervention. These will
include:
i) The SF36 health status profile which we will use to gen-
erate Mental (MCS) and Physical Component Summary
Scales (PCS) [26,27,32].
ii) The Newcastle Diabetes Symptoms Questionnaire
[28].
iii) The Bradley Treatment Satisfaction Questionnaire
[29].
Patient costs questions will be developed by the study
health economist. We have successfully used such packag-
es of questionnaires within trials before and have
achieved response rates in excess of 70% in similar surveys
in this region. [33].
Sample size considerations
On the basis of previous work we have made the follow-
ing assumptions. The mean number of patients per prac-
tice for whom we will be able to collect process data will
be 30 and the ICC (a measure of the lack of independence
of responses from patients from the same practice) calcu-
lated from our local data is 0.14 for measures of process
(whether a blood pressure measurement and whether an
HbA1c measurement has been recorded in a 12 month pe-
riod). Standard methods for determining the sample size
requirements for a cluster randomised trial [34] indicate
that we need 60 practices to detect a difference of 15%
(42.5% v 57.5%) with 80% power assuming a signifi-
cance level of 5%. Assessment of outcome of care will be
based on health status scales such as the SF-36. Previous
work has shown that this type of intervention is likely to
produce an effect size of approximately 0.25 in such meas-
ures [32] and that the ICCs for such measures will be ap-
proximately 0.07. The most efficient study design (that
minimises the number of patients required) is one that
makes use of all the available practices. A sample of 27 pa-
tients from each of 61 practices will give us 85% power to
detect an effect size of 0.25 assuming a significance level
of 5%. With a predicted response rate of approximately
70% (based on our experience in the COGENT study
[33]) after two reminders, our starting sample size will
need to be 2379 patients (approximately 39 patients per
practice).
Principles of data analysis
Analysis will be by intention to treat. Multilevel model-
ling (using the MlwiN package [35]) will be used to take
into account the clustering of patients within practices
[36]. Both binary variables (when a process was undertak-
en or not) and continuous variables (such as the physical
health component of the SF-36) can be analysed using
these techniques. For both types of variable, variation be-
tween practices will be fitted as a random effect and the
difference between intervention and control practices will
be fitted as a fixed effect. In the case of binary variables, a
logit link function will be used.
Economic evaluation
The economic impact of implementing the new structured
recall and management system will be evaluated in terms
of the marginal costs of adapting and running the system;
the costs of developing and disseminating the guidelines;
the educational activities for intervention practices; the
implications for the use of health care services; and the
costs to the patients and their carers. The benefits will be
measured as described earlier on in the clinical study. The
estimation of health service resource use will relate to di-
abetes-specific clinical visits, tests, investigations, and pro-
cedures. This data will be routinely collected as part of the
management system implementation and subsequent
costing, using health service pay and price data, will be
undertaken using a mixed approach based on micro-cost-
ing and gross-costing methods [37]. Use of drugs, referrals
to secondary care and the impact of the intervention on
the change of use of patients' and their carers' time will
also be monitored through postal questionnaires at the
end of the follow-up period. A sensitivity analysis will be
undertaken to test the robustness of the results to the un-
certainty not related to sampling variations and to en-
hance the generalisability of the results [38]. We are aware
that the costs of the system might be balanced only in the
longer term against the cost savings related to averted
complications [39–41]. However, the assessment of the
benefits in terms of final outcomes (e.g lives saved, or QA-
LYs) and long term costs is beyond the objective of the
present study.
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